Cancer Research UK and partners have committed £5.5m in funding to form a world-leading research team tasked with making personalised medicine a reality for people with bowel cancer. The CRC-STARS (Colorectal Cancer — Stratification of Therapies through Adaptive Responses) initiative will bring together over 40 research experts from across the UK, Spain, Italy and Belgium – including Dr Kevin Myant from the Institute of Genetics and Cancer (IGC) – to find kinder, better treatments for the disease, which kills 16,800 people in the UK every year. Joining forces will enable them to use their combined expertise across multiple research areas, and pair clinical trial data with cutting-edge technology.Bowel cancer, also known as colorectal cancer, is the second most common cause of cancer deaths in the UK. Despite this, treatment options remain limited, particularly for patients who are diagnosed at later stages of the disease.CRC-STARS is jointly funded by Cancer Research UK (£2m), the Bowelbabe Fund for Cancer Research UK (£2m), philanthropic support from Bjorn Saven CBE and Inger Saven (£1m), and the Scientific Foundation of the Spanish Association Against Cancer (FCAECC, €600,000 [~£500,000]). The CRC-STARS initiative strengthens the collaboration between different research groups and countries, allowing us to address some of the most pressing problems in the treatment of colorectal cancer. We’re all really excited to get started. Dr Kevin Myant Principal Investigator, Edinburgh Cancer Research Kevin Myant Research Group Tags 2025 Publication date 02 Apr, 2025
